KR0131515B1 - Pharmaceutical composition for animals - Google Patents
Pharmaceutical composition for animalsInfo
- Publication number
- KR0131515B1 KR0131515B1 KR1019940010312A KR19940010312A KR0131515B1 KR 0131515 B1 KR0131515 B1 KR 0131515B1 KR 1019940010312 A KR1019940010312 A KR 1019940010312A KR 19940010312 A KR19940010312 A KR 19940010312A KR 0131515 B1 KR0131515 B1 KR 0131515B1
- Authority
- KR
- South Korea
- Prior art keywords
- tml
- otc
- pharmaceutical composition
- present
- animals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 동물용 약제조성물에 관한 것으로서, 더욱 상세하게는 옥시테트라사이클린과 티아물린이 6 : 1 ∼ 18 : 1의 중량비로 함유됨으로써 동물, 특히 돼지의 세균성 설사 또는 기관지 폐렴의 치료와 예방에 유용한 동물용 약제조성물에 관한 것이다. 티아물린(Tiamulin, 이하 TML이라 함)은 담자균의 일종인 플레우로투스 무틸루스(Pleurotus mutilus)의 배양에 의해 얻어진 플레우로무틸린(Pleuromutilin)의반합성 유도체이다. 플레우로쿠틸린은 1951년 카바나(Kavanagh) 등에 의해 발견되어진 디터펜계 항생물질로서 그람양성균, 일부 그람음성균, 그외의 트레포네마(Treponema), 마이코플라즈마(Mycoplasma) 등에 대해서도 생물활성을 나타내는 특징적인 물질이다. 이 물질은 1963년 버치(Birch) 등에 의해 그 화학구조가 해명된 이래 플레우로무틸린의 대부분의 유도체가 각종 동물의 감영증에 대해 예방 및 치료효과가 있고 각종 유도체중 푸마레이트 티아물린(Fumarate Tiamulin)의 항균활성이 가장 우수한 것으로 확인되고 있다. 현재 TML로 일반적으로 사용되는 표준물질은 그 화확명이 14-디옥시-14[(2-디에틸아미노에틸)-티오아세톡시] 무틸린 하이드로겐 푸마레이트로서 일반적으로 후마르산 티아물린(Tiamulin hydrogen fumarate)으로 불리고 있으며 디터펜계 항생물질로서, 특히 돼지의 호흡기성 병원균과 적리에 대해 효력이 좋은 것으로 보고되고 있다. 한편, 옥시테트라 사이클린(Ocytetracycline, 이하 OTC라 함)은 1950년 미국의 핀레이(A. C. Finlay) 등에 의해서 스트랩토마이세스 리모수스(Streptomyces rimosus)의 산생물로서 발견된 항생물질이지만 이 이후에도 다른 방선균에서도 얻어졌다. 이 OTC는 양성물질로서 각종 염과 킬레이트 화합물이 만들어지지만 제제로는 염산염, 염기 및 칼슘염 등이 사용되고 있으며, 동물용제제로는 염산염 및 모노알킬트리메틸 암모니움 칼슘염이 사료 첨가제 등으로 사용되고 있다. 또한 OTC는 그람양성균, 그람음성균, 렙토스피라, 항산균 및 일부 원충 등의 병원성 미생물의 단백질 합성을 억제함으로써 균의 분열증식을 차단시킴으로서 정균작용을 나타내는 광범위 항생물질로, 특히 장내 미생물 병원균에 효력이 좋은 항생제로 세계 여러나라에서 가축의 질병예방제 및 치료제로 이용되고 있다. 상기와 같은 TML과 OTC는 수의 임상분야에서 많이 사용되고 있는 항생물질이지만 이들의 혼합제제에 대한 약리학적 연구는 국내외적으로 거의 이루어지고 있지 않는 실정이다. 최근 TML과 OTC의 혼합 사용시의 상승작용과 돼지에 있어서 대장균증, 적리, 기관지폐렴의 예방에 있어서의 적용 가능성에 대한 연구가 진행되었는데, 이 연구는 OTC와 TML을 중량비로 3 : 1로 함유한 디스크를 가지고 디퓨전(diffusion) 방법으로 시험되었고 그 결과 TML이나 OTC 단독으로 사용했을 때보다 몇 종류의 병원균에 대한 항균력이 더욱 강해졌으며, 실제 돼지에 사용할 때도 대장균증, 돈적리, 폐렴 등의 발생을 현저히 감소시킨다는 보고가 있다. 그러나, 상기 OTC와 TML의 혼합 사용기술은 그 중량비가 3 : 1인 경우에만 국한된 것이며 혼합범위에 대한 실험의 예가 보고되어 있지 않고, 또한, TML의 원가가 OTC에 비해 약 10배인 점을 감안하면 약효가 우수하고 보다 경제적인 OTC와 TML의 혼합제제의 개발이 절실히 요구되고 있다. 따라서 본 발명의 실험은 두 항생제의 여러 농도범위에서 혼합시 항균효력을 검정하고저 하였으면 이에따라 본 발명자들은 상기와 같은 종래 혼합범위인 OTC와 TML의 3 : 1범위에서 벗어나 항균력을 더욱 높이기 위하여 노력한 결과 OTC와 TML의 혼합 중량비를 6 : 1 내지 18 : 1로 조절함으로써 경제적이면서 가축의 병원성 미생물의 억제효과가 우수한 본 발명의 OTC와 TML의 혼합 약제조성물을 개발하게 되었다. 본 발명은 경제적이면서 가축의 병원성 미생물의 억제효과가 우수한 OTC와 TML의 혼합 약제조성물을 제공하는데 그 목적이 있다. 이하, 본 발명을 상세히 설명하면 다음과 같다. 본 발명은 옥시테트라사이클린과 티아물린이 6 : 1 ∼ 18 : 1의 중량비로 혼합되어 이루어진 동물용 약제조성물에 관한 것이다. 이와같은 본 발명을 더욱 상세히 설명하면 다음과 같다.The present invention relates to a pharmaceutical composition for animals, and more particularly, by containing oxytetracycline and thiamulin in a weight ratio of 6: 1 to 18: 1, which is useful for the treatment and prevention of bacterial diarrhea or bronchial pneumonia in animals, particularly swine. It relates to a pharmaceutical composition for animals. Tiamulin (hereinafter referred to as TML) is a semisynthetic derivative of Pleuromutilin obtained by culturing Pleurotus mutilus, a kind of basidiomycetes. Pleurocutillin is a diterpene antibiotic discovered by Kavanagh in 1951 and is characterized by biological activity against gram-positive bacteria, some gram-negative bacteria, treponema, and mycoplasma. to be. Since the chemical structure was elucidated by Birch et al. In 1963, most of the derivatives of pleuromutillin have preventive and therapeutic effects on the sensitization of various animals, and among the various derivatives, Fumarate Tiamulin It is confirmed that the antimicrobial activity of) is the best. A standard commonly used as TML is currently 14-dioxy-14 [(2-diethylaminoethyl) -thioacetoxy] mutiline hydrogen fumarate, which is commonly used for Tiamulin hydrogen fumarate. As a diterpene antibiotic, it has been reported to be particularly effective against swine respiratory pathogens and isolates. Meanwhile, oxytetracycline (OTC) is an antibiotic discovered by AC Finlay of the United States in 1950 as a product of Streptomyces rimosus, but has since been obtained from other actinomycetes. lost. OTC is a positive substance, and various salts and chelating compounds are made, but hydrochloride, base, and calcium salt are used as the preparation, and hydrochloride and monoalkyltrimethyl ammonium calcium salt are used as feed additives and the like for animal solvents. In addition, OTC is a broad-spectrum antibiotic that exhibits bacteriostatic action by inhibiting the proliferation of bacteria by inhibiting the protein synthesis of pathogenic microorganisms such as Gram-positive bacteria, Gram-negative bacteria, Leptospira, antibacterial bacteria and some protozoa. As an antibiotic, it is used in many countries around the world to prevent and treat livestock diseases. TML and OTC as described above are antibiotics that are widely used in veterinary clinical fields, but pharmacological studies of their formulations are rarely performed at home and abroad. Recently, a study on the synergy of the mixed use of TML and OTC and its applicability in the prevention of E. coli, etiology, and bronchial pneumonia in pigs has been conducted, and this study included a disc containing OTC and TML in a weight ratio of 3: 1. It has been tested by diffusion method and has resulted in stronger antimicrobial activity against several pathogens than TML or OTC alone, and significantly reduces the incidence of Escherichia coli, swine pneumonia and pneumonia when used in pigs. There is a report. However, the mixed use technology of the OTC and TML is limited only when the weight ratio is 3: 1, and an example of the experiment on the mixing range is not reported, and considering that the cost of the TML is about 10 times that of the OTC, There is an urgent need for the development of a mixture of OTC and TML, which is excellent in efficacy and more economical. Therefore, the experiments of the present invention was to verify the antimicrobial efficacy when mixing at various concentration ranges of the two antibiotics accordingly the present inventors tried to further increase the antimicrobial activity beyond the 3: 1 range of OTC and TML of the conventional mixing range as described above By adjusting the mixed weight ratio of OTC and TML to 6: 1 to 18: 1, it was possible to develop a mixed pharmaceutical composition of the OTC and TML of the present invention that is economical and excellent in inhibiting the pathogenic microorganisms of livestock. An object of the present invention is to provide a mixed pharmaceutical composition of OTC and TML that is economical and excellent in inhibiting the pathogenic microorganisms of livestock. Hereinafter, the present invention will be described in detail. The present invention relates to an animal pharmaceutical composition comprising oxytetracycline and thiamulin in a weight ratio of 6: 1 to 18: 1. Referring to the present invention in more detail as follows.
본 발명은 항생물질인 OTC와 TML의 혼합비율을 조정하여 경제적이면서도 병원성 균주에 대한 항균활성이 우수한 새로운 조성의 동물 약제조성물에 관한 것으로서, 본 발명에서는 OTC와 TML 사이의 상호작용을 규명하고 혼합비간의 상관 관계를 알아보기 위해 항생제 다제 내성균주(multi-resistant microorganism) 즉, 각종 세균성 질병에 이환된 닭, 돼지 및 소로부터 분리한 그람양성 및 음성세균에 대한 OTC와 TML의 복합제제의 항균효과를 최소 발육저지 농도(Minimum Inhibition Concentration, MIC)로 시험하여 측정한다. 본 발명에서 OTC와 TML의 혼합비율은 중량비로 6 : 1 미만이면 혼합제제의 내성 병원균에 대한 항균효력이 저하될 뿐아니라 TML의 높은 가격으로 인해 비경제적이며, 18 : 1을 초과하면 경제적으로는 유리하나 병원균에 대한 항균효력이 저하되어 목적하는 바의 효과를 거두기 어려운 문제가 있다. 본 발명은 상기한 바와같이 OTC와 TML을 상기 비율로 혼합하여 제조함으로써 항생제 저항균주의 출현을 억제할 수 있고, 병용투여시 용량을 감소시킴으로써 단독 투여시 보다 독성을 감소시킬 수 있으며 복합감염질병이 발생하였을 때 보다 효과적으로 작용할 수 있을 뿐아니라 원가가 높은 TML의 함량을 줄이면서도 병원균에 대한 항균효력이 우수한 효과가 있어 해당동물의 질병의 예방과 치료에 유용하게 사용될 수 있다.The present invention relates to an animal pharmaceutical composition of a novel composition that is economical and excellent antimicrobial activity against pathogenic strains by adjusting the mixing ratio of antibiotics OTC and TML, and in the present invention, the interaction between OTC and TML and To investigate the correlation, the antimicrobial effect of the combination of OTC and TML on the antimicrobial multi-resistant microorganism, that is, Gram-positive and negative bacteria isolated from chickens, pigs and cows affected by various bacterial diseases was minimized. Measured by Minimal Inhibition Concentration (MIC). In the present invention, when the mixing ratio of OTC and TML is less than 6: 1 by weight, the antimicrobial efficacy of the mixed agent to the resistant pathogens is not only lowered, but also uneconomical due to the high price of TML. Advantageously, the antibacterial effect on pathogens is lowered, which makes it difficult to achieve the desired effect. The present invention can suppress the emergence of antibiotic resistance strains by mixing OTC and TML in the above-mentioned ratio as described above, and can reduce the toxicity when administered alone by reducing the dose when co-administered. Not only can it work more effectively when it occurs, but also has a high cost-effective antimicrobial effect against pathogens while reducing the content of high TML can be useful for the prevention and treatment of diseases in the animal.
이하, 본 발명을 실시예의 의거 상세히 설명하면 다음과 같은 바, 본 발명이 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following Examples, which are not intended to limit the present invention.
[실시예 1 ∼ 5, 비교예 1 ∼ 5][Examples 1-5, Comparative Examples 1-5]
그람음성 균주인 대장균(Escherichia coli) JM(A 균주), 대장균 70(B 균주), 보데텔라 브론키셉티카(Bordetella bronchiseptica) (C 균주) 및 살모넬라 티피무리움(Salmonella typhimurium)(D 균주), 그람양성 균주인 바실러스 섭틸리스(Bacillus subtilis)(E 균주)와 스태필로코커스 아우레우스(Staphylococcus aureas)(F 균주)를 각각 항균제 감수성 시험배지인 뮐러 힌톤(Muller-Hinton) 배지에 다중접종(muotiple innoculation)법으로 접종하여 배양하고 여기에 옥시테트라사이클린과 티아물린을 다음 표의 비율에 따라 혼합, 첨가하여 각 병원균에 대한 MIC 값을 측정하여 다음 표에 나타내었다.Gram-negative strains Escherichia coli JM (Strain A), Escherichia coli 70 (B strain), Bodetella bronchiseptica (Strain C) and Salmonella typhimurium (Strain), Gram Positive strains Bacillus subtilis (Strain E) and Staphylococcus aureas (Strain F) were each inoculated with mutiple on Muller-Hinton medium, an antimicrobial susceptibility test medium. Inoculation was inoculated and cultured. Oxytetracycline and thiamulin were mixed and added according to the ratio of the following table, and the MIC values for each pathogen were measured and shown in the following table.
MIC 측정방법은 뮐러 힌톤 아가배지에 두 항생제가 실시예에 표기된 농도범위에서 뮐러 힌톤 아가에 2단계 희석법으로하여 농도를 조절한 후 각 균주를 배지에 접종하여 37℃에서 10 ∼ 20시간 배양한 후 관찰하여 균의 성장이 없는 가장 낮은 농도의 배지에서 항생제 농도를 조사하여 최소 희석저지농도(MIC)로 결정하였다. 이는 NCCLS(National Committee for Clinical Laboratory Standards) 방법에 준하였다. 참고로 상기 각 균주들은 각각 동물의 장설사증, 위축성비염, 유방염 등의 병원균이다.The MIC method is to control the concentration of two antibiotics in Müller Hinton agar medium by two-stage dilution method in Müller Hinton agar in the concentration range indicated in the Example, inoculate each strain into the medium and incubate at 37 ° C for 10-20 hours. The minimum dilution inhibitor concentration (MIC) was determined by examining the antibiotic concentration in the lowest concentration medium without bacterial growth. This was in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) method. For reference, each of the strains is a pathogen such as diarrhea, atrophic rhinitis and mastitis of each animal.
상기 표에서 나타난 것처럼 OTC와 TML을 단독으로 사용시 나타난 MIC값보다 실시예의 혼합비율(6 : 1 ∼ 18 : 1)일 경우 각각의 성분에 대한 MIC 값이 평균적으로 약 4배 낮아져 이들 두 항생제 간에 상승작용이 있음을 보여주었다. 그리고 비교에 1, 2, 3의 혼합비율(1 : 1, 3 : 1, 21 : 1)인 경우 나타난 MIC값 보다도 평균적으로 2배 낮아져 실시예의 혼합비율(6 : 1 ∼ 18 : 1)이 더 우수한 항균력을 나타내었다. 이는 두 항생제가 적절 농도범위에서 혼합되어야 우수한 항균약리 작용이 존재하는 것을 실험결과로 알 수 있었으며, 이러한 결과의 관찰은 생산 원가의 절감에 크게 기여할 수 있을 뿐아니라 가축질병의 치료효율을 증대시키고 약품의 축체내 잔류문제도 보다 효율적으로 최소화시킬 수 있다.As shown in the table above, when the mixing ratio (6: 1 to 18: 1) of the Example was lower than the MIC value when OTC and TML were used alone, the MIC value for each component was about 4 times lower on average, and thus increased between these two antibiotics. It has been shown to work. In the comparison, the mixing ratio of 1, 2, 3 (1: 1, 3: 1, 21: 1) is 2 times lower than the MIC value displayed on average, so that the mixing ratio (6: 1-1-18: 1) of the example is more. Excellent antimicrobial activity was shown. Experimental results show that the antimicrobial pharmacological action is present only when the two antibiotics are mixed in the appropriate concentration range, and the observation of these results can greatly reduce the production cost, increase the treatment efficiency of livestock diseases, and Residual problems in the shaft can also be minimized more efficiently.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940010312A KR0131515B1 (en) | 1994-05-11 | 1994-05-11 | Pharmaceutical composition for animals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019940010312A KR0131515B1 (en) | 1994-05-11 | 1994-05-11 | Pharmaceutical composition for animals |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950031083A KR950031083A (en) | 1995-12-18 |
KR0131515B1 true KR0131515B1 (en) | 1998-04-17 |
Family
ID=19382877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940010312A KR0131515B1 (en) | 1994-05-11 | 1994-05-11 | Pharmaceutical composition for animals |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR0131515B1 (en) |
-
1994
- 1994-05-11 KR KR1019940010312A patent/KR0131515B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR950031083A (en) | 1995-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5001234B2 (en) | Treatment and prevention of diseases and infections in pigs and poultry | |
US4904647A (en) | Antimicrobial pharmaceutical composition | |
CN101829082A (en) | Method for preparing veterinary injection of spectinomycin hydrochloride and lincomycin hydrochloride | |
KR0131515B1 (en) | Pharmaceutical composition for animals | |
US2907693A (en) | Antibacterial compositions comprising a tetracycline-type antibiotic and an alkyl phenoxyethoxyethyl dialkylbenzyl ammonium salt | |
KR20140143497A (en) | Novel strain of Bacillus amyloliquefaciens and animal feed additive containing it | |
GB2585132A (en) | Composition for reducing antimicrobial resistance | |
EP0354453B1 (en) | Antimicrobial agent for animals | |
JP4823900B2 (en) | Ibrocin for the treatment of diseases caused by Brachyspirapirosicoli or Ornithobacterium rhinotracheale | |
EP0597167B1 (en) | Veterinary preparation containing an antibiotic mixture of gentamicin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding | |
US6660262B2 (en) | Broad spectrum antimicrobial compound and treatment | |
GB2103085A (en) | Antimicrobial compositions containing primycin and doxycycline and/or sisomycin or a derivative thereof | |
KR100295742B1 (en) | Complex antibiotic composition for animal bacterial infections | |
US4404189A (en) | Synergistic antimicrobial compositions | |
KR102489659B1 (en) | Composition of antimicrobial complex for animal comprising amphenicols and aminoglycosides | |
KR20130085706A (en) | Feed additives alternatives to antibiotics for preventing and treating bacterial gastrointestinal disease | |
KR950009945B1 (en) | "veterinary preparation containing an antibiotic mixture of gentamicin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding | |
RU2530619C1 (en) | Method of prevention of pneumonia in piglets | |
US3082150A (en) | Antibacterial compositions and methods of using same | |
JP3009203B2 (en) | Campylobacter Growth Inhibitors in Poultry or Livestock | |
KR20070111602A (en) | A pharmaceutical composition for colitis induced by pernicious enteric bacterium | |
CN1242689C (en) | Terramycin formate feed additive and its preparation | |
KR100371091B1 (en) | The composition of antibacterial complex for animal | |
JPH11116474A (en) | Antimicrobial mixture | |
CA1155765A (en) | Synergistic antimicrobial compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20100901 Year of fee payment: 14 |
|
LAPS | Lapse due to unpaid annual fee |